Dotmatics partners with RockStep Solutions to provide an integrated solution for digitalized in vivo drug discovery
Bishop’s Stortford, UK, and Portland, ME, USA, 12 October 2021: Dotmatics Ltd, an Insightful Science company that provides leading-edge scientific informatics software to drive the automation of lab data workflows and accelerate critical R&D discovery, today announced a partnership with RockStep Solutions (RockStep), a developer of software tools for managing data and operations for in vivo…
seqWell appoints new commercial team, led by Chief Commercial Officer Steve Smith
Beverly MA, US, 05 October 2021: seqWell, a global provider of next-generation sequencing (NGS) library technologies based on its proprietary plexWell™ multiplexing platform, today announced five appointments to its commercial team.
CrestOptics introduces DeepSIM super resolution confocal microscope module
Rome, IT, 04 October 2021: CrestOptics SpA, a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, today announced the launch of DeepSIM, a super resolution module designed to enhance the imaging capabilities of confocal microscope systems. The DeepSIM module can be used with Crest’s X-light V3 spinning disk, or alternative…
Bio-Rad launches IgA and IgM SARS-CoV-2 Bio-Plex pro immunoassay panels to study COVID-19 antibody response
HERCULES, Calif.–September 30, 2021: Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Bio-Plex™ Pro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens. The panels are for research use only (RUO).
Gyros Protein Technologies introduces Gyrolab AAV9 Titer Kit to support AAV-based cell and gene therapy production
Uppsala, Sweden, 30 September 2021: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® AAV9 Titer Kit for rapid determination of physical titer in adeno-associated virus serotype 9 (AAV9) vector-based cell and gene therapy manufacturing.
Avacta announces achievement of pre-clinical development milestone in LG Chem Life Sciences partnership
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that a pre-clinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences, the life sciences division of the…
FUJIFILM Irvine Scientific begins customer qualification of European manufacturing facility
SANTA ANA, California: FUJIFILM Irvine Scientific, Inc. today announced that it completed construction and started the commissioning phase of its new manufacturing facility in Tilburg, the Netherlands. The commissioning milestone marks the beginning of validating the facility and equipment in anticipation of full operations starting in late 2021. The new facility will join manufacturing locations…
ELRIG UK launches equality, diversity, and inclusion guiding principles at Drug Discovery 2021
York, UK: The European Laboratory Research & Innovation Group (ELRIG) UK today announced it will launch its equality, diversity, and inclusion (EDI) guiding principles at Drug Discovery 2021. The principles were developed with the support of Equality, Diversity and Inclusion in Science and Health (EDIS), a coalition of organisations working to improve EDI within the science and health…
Dotmatics appoints Mike McKee as new president to lead the industry transformation to data-driven scientific research
Highly accomplished technology CEO appointed to accelerate the company’s immense scale and capitalise on unprecedented momentum.
Optibrium appoints Professor Andy Black as non-executive Chair
Optibrium™, a developer of software for drug discovery, today announced the appointment of Professor Andy Black as non-executive Chair of its Board of Directors. Following the company’s recent investment from Kester Capital, the appointment will help to continue Optibrium’s strong commercial growth calling on Andy’s extensive experience in leading strategic expansion. This will include the…
FairJourney Biologics announces THE ANTIBODY SERIES 2022
Porto, Portugal –FairJourney Biologics SA, leader in the discovery and optimisation of antibodies, today announced, after the overwhelming success of the 2021 ANTIBODY SERIES conference, planning for a larger scale 2022 ANTIBODY SERIES is underway.
GammaDelta Therapeutics initiates first-in-human Phase 1 trial of GDX012 for treatment of acute myeloid leukaemia
London, UK, 15 Sept 2021: GammaDelta Therapeutics Ltd. (GDT), a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer, today announced that it has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML). GDX012 is an allogeneic, non-engineered, variable delta 1 (Vδ1) gamma…
Insightful Science acquires FCS Express, strengthening its leadership position as the Cloud for Scientific Discovery
Insightful Science, the software company enabling the Cloud for Scientific Discovery, announced today that it has completed the transaction to acquire De Novo Software, the maker of FCS Express™. FCS Express is the fastest-growing flow cytometry data analysis solution in the industry.
Optibrium releases 3D ligand-based design module for StarDrop drug discovery software
Optibrium Ltd, a developer of software for drug discovery, has announced the release of the latest version of StarDrop™, its comprehensive software platform for small molecule design, optimisation and data analysis. StarDrop is used by more than 160 organisations worldwide, including many of the top global pharmaceutical companies. The release of StarDrop 7.1 further expands the platform’s…
Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces new appointments to its Scientific Advisory Board (SAB), reflecting the progress of the Therapeutics Division and Avacta’s transition to a clinical stage Company.
Avacta appoints Dr Fiona McLaughlin as Chief Scientific Officer of its Therapeutics Division
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces the appointment of Dr Fiona McLaughlin as Chief Scientific Officer of its Therapeutics Division effective immediately.
FairJourney Biologics expands into new facilities in Porto, Portugal
FairJourney Biologics SA (FJB), leader in the discovery and optimisation of antibodies, announced it has relocated into a larger, newly purpose-built research center in Porto, Portugal. The new premises support the Company’s expansion and plans for further growth.
Avacta appoints Dr. Mark Goldberg as Non-Executive Director
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces the appointment of Dr Mark Goldberg as Non-executive Director to the Board with immediate effect.
ELRIG UK announces Drug Discovery 2021 event to host SLAS’s Innovation AveNEW
The European Laboratory Research & Innovation Group (ELRIG) UK has announced the programme details for Drug Discovery 2021, which will take place at the Exhibition Centre ACC in Liverpool, UK, from 19–20 October.
ERS Genomics and Cellular Engineering Technologies enter CRISPR/Cas9 license agreement
License allows Cellular Engineering Technologies to develop, manufacture and commercialize next generation stem cell lines using CRISPR/Cas9 technology
Avacta announces first patient dosed in AVA6000 Pro-Doxorubicin Phase I clinical trial
Cambridge and Wetherby... Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the first patient has been dosed in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin.
FUJIFILM Irvine Scientific becomes sole worldwide distributor of Presagen’s Life Whisperer
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection.
Dotmatics to deliver the foundation for Croda’s R&D digital programme: artificial intelligence and data mining
Bishop’s Stortford, UK... Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has been selected by Croda International Plc to implement its Research and Development (R&D) digital programme. Croda is the name behind the high-performance ingredients…
ERS Genomics and Japan SLC sign CRISPR/Cas9 licence agreement
Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models.
Orbit Discovery announces $7.6 million funding to accelerate growth in peptide discovery business
Oxford...Orbit Discovery Ltd, a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million (USD) in funding.